Get the Stockscreener App
23.17
0.73%
-0.17
After Hours:
23.17
Bicara Therapeutics Inc stock is traded at $23.17, with a volume of 296.88K.
It is down -0.73% in the last 24 hours and down -11.23% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
See More
Previous Close:
$23.34
Open:
$23.09
24h Volume:
296.88K
Relative Volume:
0.42
Market Cap:
$1.53B
Revenue:
-
Net Income/Loss:
$-137.95M
P/E Ratio:
-9.185
EPS:
-2.5226
Net Cash Flow:
$-107.11M
1W Performance:
-1.11%
1M Performance:
-11.23%
6M Performance:
+24.97%
1Y Performance:
+92.12%
1-Day Range:
$22.85
$23.46
1-Week Range:
$22.61
$24.35
52-Week Range:
$10.29
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
23.17 | 1.61B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | BofA Securities | Buy |
| Jan-29-26 | Initiated | Citizens JMP | Mkt Perform |
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Jennifer Larson Net Worth (2026) - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
BMO Capital Initiates Bicara Therapeutics at Outperform - Moomoo
Bicara Therapeutics Initiated at Outperform by BMO Capital - Moomoo
Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History - Yahoo Finance
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35 - Bitget
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Yahoo Finance
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com India
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - Sahm
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX - MarketBeat
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board - Endpoints News
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX - MarketBeat
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis - kalkine.ca
Janus Henderson Group (BCAX) reports 3.17M Bicara Therapeutics shares in 13G/A - Stock Titan
Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL) - The Globe and Mail
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) - Yahoo Finance
Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results - webull.com
Bicara Therapeutics CEO Claire Mazumdar Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Bicara Therapeutics CFO Ivan Hyep Executes Sale of 12,500 Shares via 10b5-1 Plan - Kalkine Media
Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock - MarketBeat
Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan - Stock Titan
Bicara Therapeutics (BCAX) CEO exercises 10K options and sells 10K shares under plan - Stock Titan
Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares - Stock Titan
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds (NASDAQ:BCAX) - Seeking Alpha
BCAX Maintained by Wells Fargo -- Price Target Raised to $23.00 - GuruFocus
Wells Fargo & Company Boosts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $23.00 - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning - Investing.com
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning By Investing.com - Investing.com South Africa
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BCAX SWOT Analysis: Financial Losses Highlighted in 10-Q Filing - GuruFocus
Bicara Therapeutics announces CEO transition, CFO appointment By Investing.com - Investing.com UK
Bicara Therapeutics stock price target raised to $39 by BTIG - Investing.com Australia
Bicara Therapeutics Inc. Stock 12‑Month Price Target Raised to $32.46, Implies 17% Upside - TradingView
Bicara Therapeutics (BCAX) deepens R&D investment while holding $497M in cash - Stock Titan
Bicara Therapeutics Inc. 2026: Revenue ($55.76M), Net income ($55.44M), EPS ($0.82) — 10-Q Summary - TradingView
Bicara Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Bicara Therapeutics Inc Stock (BCAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hyep Ivan | Chief Financial Officer |
Aug 10 '26 |
Sale |
27.97 |
12,500 |
349,591 |
129,855 |
| Mazumdar Claire | Chief Executive Officer |
Aug 10 '26 |
Option Exercise |
3.79 |
10,000 |
37,898 |
372,152 |
| Mazumdar Claire | Chief Executive Officer |
Aug 10 '26 |
Sale |
27.98 |
10,000 |
279,750 |
362,152 |
| Cohlhepp Ryan | President and COO |
Aug 10 '26 |
Option Exercise |
3.79 |
18,750 |
71,059 |
200,391 |
| Cohlhepp Ryan | President and COO |
Aug 10 '26 |
Sale |
27.98 |
18,750 |
524,533 |
181,641 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):